10x Genomics sued Element Biosciences, alleging the Aviti24 multiomic spatial platform infringes spatial-technology patents licensed from Harvard University. In its Delaware complaint, 10x cites multiple U.S. patents tied to analyte detection and selective sequencing of amplicons, seeking damages, attorneys’ fees, and a permanent injunction. Element said it disagrees with the allegations and views the lawsuit as part of a pattern of using patent portfolios to limit innovation. Element pointed to its planned launch of direct in-tissue spatial sequencing products for fresh-frozen and FFPE tissues later this year. In a separate dispute in prenatal testing, Illumina filed suit against BillionToOne for patent infringement related to non-invasive prenatal testing technologies used for fetal nucleic acid quantification and related sequencing methods. The twin legal actions highlight how IP risk is an active variable for commercializing next-gen diagnostics platforms.